Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like scanning a clinical protocol—dense tables, unfamiliar endpoints, and pages of risk factors. Seres Therapeutics adds an extra layer of complexity: live-biotherapeutic manufacturing data, royalty math from its Nestlé Health Science collaboration, and trial updates for VOWST and SER-155. If you have ever hunted through a 10-K to see how long MCRB’s cash runway lasts or waited for Form 4 alerts to gauge executive sentiment, you know the challenge.
Stock Titan solves that problem. Our AI engine converts every paragraph of a Seres Therapeutics quarterly earnings report 10-Q filing into plain-English highlights, flags new risk disclosures, and links them to key metrics. For Seres Therapeutics insider trading Form 4 transactions, you receive real-time push notifications, making Seres Therapeutics Form 4 insider transactions real-time easy to act on. Need context? One click shows how this quarter’s R&D burn compares with last year’s.
Inside the filings hub you’ll find every document the company submits to EDGAR—
- 10-K: Our summary spots pipeline timelines and royalty revenue, giving you a Seres Therapeutics annual report 10-K simplified.
- 8-K: Material news like FDA meetings or shelf offerings appear under Seres Therapeutics 8-K material events explained.
- DEF 14A: Quickly locate equity awards in the Seres Therapeutics proxy statement executive compensation.
Whether you’re tracking Seres Therapeutics executive stock transactions Form 4 or need a concise Seres Therapeutics earnings report filing analysis, our platform keeps you ahead with concise explanations, searchable text, and downloadable data. That’s Seres Therapeutics SEC filings explained simply.
Eric D. Shaff, a director of Seres Therapeutics (MCRB), received and reported the settlement of restricted stock units and a small sale of common stock under a 10b5-1 plan. On 08/15/2025 he had two non-derivative acquisitions: 391 and 333 shares issued on settlement of restricted stock units, increasing his beneficial ownership to 10,493 and 10,826 shares respectively. On 08/18/2025 he sold 217 shares at $16.65 each, which the form states were executed under a Rule 10b5-1 instruction adopted to cover taxes related to RSU vesting. The RSUs vest in scheduled installments (25% earlier vesting followed by quarterly vesting) and have no expiration date.
Insider transactions at Seres Therapeutics (MCRB): Thomas J. DesRosier, a senior executive identified as Chief Legal Officer, EVP, Co‑CEO and Co‑President, reported restricted stock unit vesting and a small sale under a preexisting Rule 10b5‑1 plan. On 08/15/2025 DesRosier had 133 and 111 restricted stock units settle into common shares (total 244 shares) and beneficially owned 7,420 and 7,531 shares respectively after those settlements. On 08/18/2025 he sold 76 shares at $16.65 per share pursuant to the 10b5‑1 instruction to cover taxes related to vesting. The filings state the RSUs vest in scheduled quarterly installments and have no expiration.
Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics (MCRB), reported equity changes on a Form 4. Restricted stock units vested and settled on 08/15/2025: 141 RSUs and 97 RSUs were reported as acquired/settled, each representing one share. A subsequent sale on 08/18/2025 disposed of 73 shares at $16.65 per share under a Rule 10b5-1 plan adopted April 13, 2023 to cover taxes related to vesting. Following these transactions the filing shows 4,548 shares beneficially owned and remaining RSU balances of 844 and 976 as reported.
Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (Ticker: MCRB), reported vesting and settlement of restricted stock units and a small sale of common stock in August 2025. On 08/15/2025 two tranches of restricted stock units were reported (133 and 97 RSUs) that represent contingent rights to receive shares; the filings show post-transaction beneficial ownership figures of 5,177 and 5,274 shares respectively. On 08/18/2025 the reporting person sold 59 shares at $16.65, executed under a Rule 10b5-1 instruction adopted March 5, 2023, described as intended solely to cover taxes relating to RSU vesting. The Form 4 is signed by an attorney-in-fact on 08/19/2025.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
